Journal of Health Care Law and Policy
Volume 16 | Issue 1

Article 4

Medical Marijuana Legislation: What We Know and Don't
Linda Simoni-Wastila
Francis B. Palumbo

Follow this and additional works at: http://digitalcommons.law.umaryland.edu/jhclp
Part of the Chemicals and Drugs Commons, Health Law Commons, Medicinal and
Pharmaceutical Chemistry Commons, and the Public Health Commons
Recommended Citation
Linda Simoni-Wastila, & Francis B. Palumbo, Medical Marijuana Legislation: What We Know - and Don't, 16 J. Health Care L. & Pol'y
59 (2013).
Available at: http://digitalcommons.law.umaryland.edu/jhclp/vol16/iss1/4

This Conference is brought to you for free and open access by DigitalCommons@UM Carey Law. It has been accepted for inclusion in Journal of
Health Care Law and Policy by an authorized administrator of DigitalCommons@UM Carey Law. For more information, please contact
smccarty@law.umaryland.edu.

MEDICAL MARIJUANA
LEGISLATION: WHAT WE KNOW—
AND DON’T
LINDA SIMONI-WASTILA
FRANCIS B. PALUMBO
I. INTRODUCTION
The use of marijuana as a medicinal agent available to individuals suffering
from pain, glaucoma, wasting syndromes associated with HIV and AIDS, nausea
from chemotherapy, and a host of other medical conditions and symptoms has
become more widely accepted.1 Over the past decade, eighteen states and the
District of Columbia have adopted medical marijuana legislation (MML) that
allows citizens to register, cultivate, and/or otherwise procure marijuana for
personal medical use.2 Additionally, the Maryland Legislature has passed a bill
that, if signed by the Governor, would provide for distribution of medical
Copyright © 2013 by Linda Simoni-Wastila & Francis B. Palumbo.
 Linda Simoni-Wastila, BSPharm, MSPH, PhD, is a professor and Vice Chair of Research at the
University of Maryland School of Pharmacy, Department of Pharmaceutical Health Services Research. I
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1. See, e.g., JANET E. JOY ET AL., MARIJUANA AND MEDICINE: ASSESSING THE SCIENCE BASE 22–
24 (1999) (listing different disorders treated with marijuana at two California Cannabis Cultivators
Clubs); Sunil K. Aggarwal et al., Medicinal Use of Cannabis in the United States: Historical
Perspectives, Current Trends, and Future Directions, 5 J. OPIOID MGMT. 153, 156 (2009) (explaining
that studies show the therapeutic potential of cannabinoids).
2. Alaska, Arizona, California, Colorado, Connecticut, Delaware, the District of Columbia,
Hawaii, Maine, Massachusetts, Michigan, Montana, Nevada, New Jersey, New Mexico, Oregon, Rhode
Island, Vermont, and Washington have all adopted MML. ALASKA STAT. § 17.37 (2010); ARIZ. REV.
STAT. ANN. §§ 36-2801–19 (Supp. 2012); CAL. HEALTH & SAFETY CODE § 11362.5 (West 2007), §
11362.7–.9; COLO. CONST. art. XVIII, § 14; COLO. REV. STAT. ANN. §§ 12-43.3-101–106 (West 2012),
§ 18-18-406.3 (West 2012), § 25-1.5-106 (West 2012); 2012 Conn. Acts 55 (Reg. Sess.); DEL. CODE
ANN. tit. 16, §§ 4901a–4926a (2011); D.C. CODE §§ 7-1671 (Supp. 2012); HAW. REV. STAT. ANN. §§
329-121–128 (LexisNexis 2008 & Supp. 2011); ME. REV. STAT. ANN. tit. 22, §§ 2421–2430-B (Supp.
2011); 2012 Mass. Legis. Serv. 369 (West); MICH. COMP. LAWS ANN. §§ 333.26421–.26430 (West
Supp. 2012); MONT. CODE ANN. §§ 50-46-301–344 (2011); NEV. CONST. art IV, § 38; NEV. REV. STAT.
ANN. §§ 453A.010–.810 (LexisNexis Supp. 2011); N.J. STAT. ANN. §§ 24:6I-1–16 (West Supp. 2012);
N.M. STAT. ANN. §§ 26-2B-1–7 (LexisNexis Supp. 2011); OR. REV. STAT. ANN. §§ 475.300–.346
(2011); R.I. GEN. LAWS §§ 21-28.6-1–12 (2011); VT. STAT. ANN. tit. 18, §§ 4472–74l (LexisNexis
Supp. 2012); WASH. REV. CODE ANN. §§ 69.51A.005–.903 (West 2012).
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marijuana through academic medical centers,3 The popularity of medical marijuana
legislation continues, with an additional eleven states considering ballot initiatives. 4
In response to the widespread acceptance of marijuana as a medical aide and
the subsequent adoption of MML, a 2009 American Medical Association Council
on Science and Public Health Report noted that the patchwork of state-based
systems that have been established for medical marijuana is ―woefully
inadequate‖ to establish even rudimentary safeguards including patie nt
information handouts that normally would be applied to the appropriate clinical
use of psychoactive substances. 5 The unwieldy patchwork of varying MML is
negatively compounded by the lack of research on both utilization and health
outcomes, as well as patterns or emerging trends in state with such legislation or
regulations. 6 Even basic information, such as the number of patients who use
marijuana in states that have removed state-level penalties, has not been clearly
established. 7 To date, research relating to medical marijuana has focused on the
historical use of cannabis as medicine, 8 current scientific and medical
understanding of marijuana‘s role in human health, 9 and the safety and efficacy
of medical marijuana. 10 Even clinical research is hampered by the reluctance of
federal funders to sponsor such research, as well as the difficulty in obtaining
government-approved strains for research purposes. 11 From a policy perspective,
there remains a paucity of research evaluating the efficacy of decriminaliza tion
3. H.B. 1101, 433rd Leg., 1st Sess. (Md. 2013).
4. PROCON.ORG, 11 States with Pending Legislation to Legalize Medical Marijuana.
http://medicalmarijuana.procon.org/view.resource.php?resourceID=002481 (last modified March 6,
2013) (Noting that as of March 2013, Alabama, Florida, Illinois, Iowa, Kansas, Kentucky, Maryland,
Missouri, New Hampshire, New York, and West Virginia all have pending legislation proposing to
legalize Medical Marijuana).
5. COUNCIL ON SCI. & PUB. HEALTH, AM. MED. ASS‘N, REPORT NO. 3, USE OF CANNABIS FOR
MEDICINAL PURPOSES 15 (2009).
6. Id.
7. Id. at 6.
8. See JOY ET AL., supra note 1, at 19 (noting marijuana‘s use as an herbal remedy before the 20th
century); Aggarwal et al., supra note 1, at 157 (calling the medicinal use of marijuana a ―rediscovery‖
rather than ―a novel medical practice‖).
9. See AM. COLL. OF PHYSICIANS, SUPPORTING RESEARCH INTO THE THERAPEUTIC ROLE OF
MARIJUANA 5, 9 (2008) (noting that side effects, methods of administration, and the availability of
alternatives are all factors used to assess the medicinal value of marijuana); see also Mohamed Ben
Amar, Cannabinoids in Medicine: A Review of their Therapeutic Potential, 105 J.
ETHNOPHARMACOLOGY 1, 3 (2006) (describing various adverse effects of medical marijuana on certain
illnesses).
10. See Sean M. Bagshaw & Neil A. Hagen, Medical Efficacy of Cannabinoids and Marijuana: A
Comprehensive Review of the Literature, 18 J. PALLIATIVE CARE 111, 111 (2002) (noting that scientific
data on the safety and efficacy of medical marijuana is currently ―inconclusive‖); Tongtong Wang et al.,
Adverse Effects of Medical Cannabinoids: A Systematic Review, 178 CAN. MED. ASS‘N J. 1669, 1671
(2008) (stating that published randomized controlled trials suggest the efficacy of medical marijuana).
11. See Gardiner Harris, Researchers Find Study of Medical Marijuana Discouraged, N.Y. TIMES,
Jan. 19, 2010, at A14 (describing how the federal government has stalled efforts to conduct marijuana
research).
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efforts in states and other jurisdictions. 12 Indeed, the general lack of knowledge
of the impact of MML on use and consequences presents a critical barrier to
designing state laws and regulations optimal for balancing treatment with
desired social and public health outcomes. The purpose of this paper is twofold:
1) to review the state of knowledge regarding key policy and legal aspects of
MML;13 and 2) to offer potential frameworks for implementing and/or
evaluating MML. 14 In Part II, the current knowledge, or lack thereof, of
important components of health outcomes and policies is discussed. These key
knowledge gaps exist in a) social and health outcomes, 15 b) means of data
collection, 16 c) medical boards‘ reaction to MML, 17 and d) dispensary models
and their successes). 18 In Part III, we address potential models for addressing
these gaps and implementing solutions.
II. MEDICAL MARIJUANA AND STATE LEGISLATION:
WHAT WE KNOW AND WHAT WE DO NOT
A. Little research has studied differences in social and public health outcomes
based on variations in state and jurisdictional Medical Marijuana Legislation
Despite the growing adoption of MML, little is known about the influence
of MML on consumption of marijuana, consumption of other controlled substances
or alcohol, and consequent health outcomes. The few studies conducted to date
present mixed and/or inconclusive findings, with some analyses finding MML
increases recreational demand 19 and others noting inconclusive evidence of such an
effect.20 Some organizations argue that as medical marijuana becomes more
12. See Diane E. Hoffmann & Ellen Weber, Medical Marijuana and the Law, 362 NEW ENG. J.
MED. 1453, 1456 (2010) (citing a lack of research as contributing to a lack of consistency in state
medical marijuana laws).
13. See infra Part II.
14. See infra Part III.
15. See infra Part II.A.
16. See infra Part II.B.
17. See infra Part II.C.
18. See infra Part II.D.
19. See Jerald G. Bachman et al., Explaining Recent Increases in Students’ Marijuana Use: Impacts
of Perceived Risks and Disapproval, 1976 through 1996, 88 AM. J. PUB. HEALTH 887, 889 (1998)
(acknowledging that recent increases in marijuana use may be attributable to declines in disapproval and
perceptions of potential risk); Rosalie Liccardo Pacula et al., Marijuana and Youth, in RISKY BEHAVIOR
AMONG YOUTHS: AN ECONOMIC ANALYSIS 271, 274–75 (Jonathan Gruber ed., 2001) (offering several
explanations for fluctuations in recreational demand of marijuana such as perceived harm and marijuana
availability).
20. See Dennis M. Gorman & J. Charles Huber Jr., Do Medical Cannabis Laws Encourage
Cannabis Use?, 18 INT‘L J. DRUG POL‘Y 160, 164 , 166 (2007) (finding no affirmative evidence that
medical marijuana laws increase use of the drug); D. MARK ANDERSON & DANIEL I. REES, INST. FOR
THE STUDY OF LABOR, DISCUSSION PAPER NO. 6112, MEDICAL MARIJUANA LAWS, TRAFFIC
FATALITIES, AND ALCOHOL CONSUMPTION 6 (2011) (explaining that MML does not necessarily
increase marijuana use, but may convert illicit users to becoming card-carrying patients).
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normative, the reduction in perceived risk will spill over into the use of recreational
marijuana.21 Indeed, the proportion of youth aged twelve to seventeen who
perceived great risk of smoking marijuana once a week declined from 54.6% in
2007 to 44.8% in 2011.22 A recent study using the 1999–2008 National Survey on
Drug Use and Health (NSDUH) found MML passage associated with decreased
perceived risk of marijuana‘s abuse potential. 23
The effect of marijuana on driving functions is unclear. Marijuana has been
associated with impaired driving functions,24 but there also is evidence that such
impairments do not lead to increased risk of collision. 25 Although no evidence links
the use of medical marijuana to impaired driving, a small body of literature
suggests states with MML experience reductions in alcohol use and, consequently,
alcohol-related fatalities, because increased use of medical and illicit marijuana
serve as alcohol substitutes.26 That is, while alcohol has a well-accepted negative
impact on driving function, marijuana‘s impact remains less clear. Indeed, analysis
of Fatal Accident Reporting System (FARS) data suggests states with MML have
experienced an 8.7% reduction in total fatal accidents and a 12.0% reduction in
alcohol-related fatalities.27 The authors surmise their findings are due to: 1)
increased use of marijuana (medical and illicit) in MML states (i.e., the substitution
effect);28 2) reduced consumption of alcohol by marijuana users; 29 and 3) an
increased tendency of marijuana users to use the substance in the privacy of their
homes, thereby reducing the risk of fatalities by reducing their exposure to
impaired driving.30

21. See Effects of Medical Marijuana Legalization, COMMUNITY ANTI-DRUG COALITIONS AM., 1,
http://www.cadca.org/files/policy_priorities/effectsmedicalmarijuana.pdf (last visited Apr. 1, 2013)
(arguing that legalization of medical marijuana leads to decreases in perceived harm and increases in
drug use).
22. SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., U.S. DEP‘T OF HEALTH & HUMAN
SERVS., RESULTS FROM THE 2011 NATIONAL SURVEY ON DRUG USE AND HEALTH 5 (2012).
23. See ANDERSON & REES, supra note 20, at 9 (finding that medical marijuana legalization in
Vermont and Rhode Island led to increased use among youth between eighteen and twenty-five years
old in those states).
24. See generally R. Andrew Sewell et al., The Effect of Cannabis Compared with Alcohol on
Driving, 18 AM. J. ON ADDICTIONS 185, 187 (2009).
25. See id. at 186; Erin Kelly et al., A Review of Drug Use and Driving: Epidemiology, Impairment,
Risk Factors and Risk Perceptions, 23 DRUG & ALCOHOL REV. 319, 326 (2004).
26. See ANDERSON & REES, supra note 20, at 6 (citing a study concluding that marijuana and
alcohol are substitutes, and another finding they were compliments). See generally Frank J. Chaloupka
& Adit Laixuthai, Do Youths Substitute Alcohol and Marijuana? Some Economic Evidence, 23 E. ECON.
J. 253 (2011) (discussing the effects of marijuana legislation on rates of youth alcohol abuse); John
DiNardo & Thomas Lemieux, Alcohol, Marijuana, and American Youth: The Unintended Consequences
of Government Regulation, 20 J. HEALTH ECON. 991, 1005 (2001) (finding that marijuana and alcohol
are substitutes).
27. ANDERSON & REES, supra note 20, at 13–14.
28. Id. at 13.
29. Id. at 42 tbl.14 (illustrating a decrease in alcohol sales after legalization of medical marijuana).
30. Id. at 21.
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B. Data Limitations
Evaluation of MML is hampered mostly by lack of data. There is no single
available dataset that allows thorough examination of medical marijuana legislation
and its influence on social and public health outcomes.31 Indeed, there are no data
routinely collected on medical marijuana use across the nation or within states with
MML.32 An ideal database would allow analyses of medical marijuana policy on
medical, social, criminal, and public health-relevant outcomes at the individual
level; however, due to privacy and cost constraints, such person-level data are
prohibitively expensive to collect and analyze.33
Because medical marijuana is not reimbursable under public or private
insurance programs, administrative health claims data are useless.34 Data collected
by law enforcement do not discriminate between marijuana used for medicinal or
recreational purposes.35 Similarly, data collected in national surveys, such as the
NSDUH and Monitoring the Future, only capture information on marijuana use and
perceptions or risk, but not the reason for use. 36 Thus, researchers cannot currently
determine the prevalence of medical marijuana use for medical indications, nor
examine the efficacy of medical marijuana and its impact on important public
health and economic outcomes.37

31. See id. at 20.
32. See id. at 7–8 (discussing drawbacks to available data on marijuana use in states, including
states that have passed MML).
33. See Lisa N. Pealer et al., The Feasibility of a Web-Based Surveillance System to Collect Health
Risk Behavior Data from College Students, 28 HEALTH EDUC. & BEHAV. 547, 548 (discussing the
difficulties methodological problems posed by traditional personal survey methods).
34. See Jeremy Smerd, Marijuana Reimbursement Claims Highlight How Pot Could be Gold for
Employers, WORKFORCE (Sept. 7, 2011), http://www.workforce.com/article/20090714/NEWS02/307
149995/marijuana-reimbursement-claims-highlight-how-pot-could-be-gold-for-employers# (noting that
health insurance companies do not reimburse patients for drugs, such as medical marijuana, that are not
FDA-approved).
35. See, e.g., FED. BUREAU OF INVESTIGATION, U.S. DEP‘T OF JUSTICE, Arrests, CRIME IN THE
UNITED
STATES,
http://www.fbi.gov/about-us/cjis/ucr/crime-in-the-u.s/2010/crime-in-the-u.s.2010/persons-arrested (follow ―Download Arrest Table Excel‖ hyperlink) (last visited Apr. 1, 2013)
(failing to distinguish between marijuana possession arrests for medicinal and recreational use).
36. See generally SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., U.S. DEP‘T OF HEALTH
& HUMAN SERVS., supra note 22, at 1 (noting that marijuana was considered an illicit drug for the
purposes of the survey without distinguishing the purpose of its use); LLOYD D. JOHNSTON ET AL., U.S.
DEP‘T OF HEALTH & HUMAN SERVS., NATIONAL SURVEY RESULTS ON DRUG USE FROM THE
MONITORING THE FUTURE STUDY, 1975–1997 6 (1998) (noting that marijuana use increased among
secondary school students without specifying the purpose of that use).
37. See generally Paul Armentano, Behind the Lack of Medical Marijuana Research: Feds
Disallowing Initiatives, HUFFPOST POLITICS: THE BLOG (Jan. 28, 2010, 2:21 PM),
http://www.huffingtonpost.com/paul-armentano/behind-the-lack-of-medica_b_439415.html (explaining
that the federal government must approve all clinical and preclinical research of marijuana, but thus far,
only funds research on the negative impacts of marijuana use).
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C. No research exists on the reaction of state medical boards to decriminalization
statutes
To date, no research has been conducted that examines the actions of state
medical boards in jurisdictions that have decriminalized medical marijuana. 38 This
lack of knowledge regarding medical board practices, guidelines, policies, and
standards of care relating to physicians who recommend medical marijuana creates
a vacuum in understanding the role that medical boards can, and possibly should,
play in ensuring that physicians recommend medical marijuana appropriately. In
their role as the entities that license and discipline physicians within a state, state
medical boards influence physician behavior by selecting which cases to
investigate and prosecute.39 Medical boards also have the authority to issue
guidance or recommendations to update physicians about state law, assist
physicians in their practice, or warn against certain practices. 40 Without such
research, however, it is difficult to know what effect MML actually has on doctors‘
prescription habits and practices.
D. The significance of differing laws relating to marijuana dispensaries is
unknown
Some MML authorizes the creation of a system of licensed dispensaries to
distribute marijuana.41 Dispensaries are not licensed pharmacies that operate under
the control of state boards of pharmacy, although apparently in California the state
board of pharmacy has been given the responsibility of inspecting dispensaries. 42 A
licensed pharmacy would need a DEA permit to dispense controlled substances and
DEA would not issue a permit to a pharmacy to distribute medical marijuana. 43
Dispensaries are a relatively novel concept and not comparable to other health care
delivery centers.44 There are few guidelines regarding how best to run a dispensary,

38. See ANDERSON & REES, supra note 20, at 19 (commenting on the lack of research on the impact
of state MML).
39. See, e.g., CAL. BUS. & PROF. CODE § 2220 (2013) (authorizing the California medical board to
enforce the provisions within the chapter against physicians and surgeons); Medical Marijuana, THE
MED. BD. CAL., http://www.mbc.ca.gov/medical_marijuana.html (last visited Apr. 1, 2013) (providing
the California Medical Board‘s recommendations on points for physicians to consider before
recommending medical marijuana in order to avoid disciplinary action).
40. See generally Drew Carlson & James N. Thompson, The Role of State Medical Boards, 7
VIRTUAL ETHICS 1 (2005), http://virtualmentor.ama-assn.org/2005/04/pdf/pfor1-0504.pdf (discussing
the role of state medical boards and how they are responsible for establishing standards and guidelines
for physicians).
41. See Hoffmann & Weber, supra note 12, at 1456 tbl.2 (listing states that have enacted MML that
allow for establishment of dispensaries in various forms).
42. CAL. BD. OF PHARMACY, 2013 LAWBOOK FOR PHARMACY 14 (2009).
43. 21 U.S.C. § 822 (1999).
44. See generally LEIYU SHI & DOUGLAS A. SINGH, ESSENTIALS OF THE U.S. HEALTH CARE
SYSTEM 24 (2d ed. 2010) (describing the various subsystems that provide the framework for health care
delivery in the United States).
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although private citizens and organizations have promulgated some best practice
guidelines.45 To date, no research has compared or contrasted the practices and
characteristics of dispensaries in different states, although there is one study of
dispensary policies within California. 46
While a handful of studies compare and contrast different MML,47 no attempt
has been made to analyze the components of the different legal frameworks in
order to place them on a continuum so that the impact of different legal structures
can be compared against specific outcome measures. 48 In Part III, potential models
for gathering information on differing policies and outcomes are proposed.
III. POTENTIAL MODELS: DISPENSARIES, REMS, AND
PRESCRIPTION DRUG MONITORING PROGRAMS (PDMPS)
While each state‘s MML is designed to meet similar goals, the laws vary in
many important ways, including limits on the quantity of marijuana that may be
possessed or cultivated,49 authorization to sell marijuana through dispensaries, 50
regulation of dispensaries,51 approved conditions of use,52 regulation of use, 53

45. See, e.g., Eric Markowitz, How to Open a Medical Marijuana Dispensary, INC. (May 27,
2011), http://www.inc.com/guides/201105/how-to-open-a-medical-marijuana-dispensary.html (offering
insight on expected costs and revenues to opening a medical marijuana dispensary).
46. NANCY J. WILLIAMS, ET AL., CAL. CTR. FOR POPULATION RESEARCH, EVALUATING MEDICAL
MARIJUANA DISPENSARY POLICIES: SPATIAL METHODS FOR THE STUDY OF ENVIRONMENTALLY-BASED
INTERVENTIONS (2011).
47. See Robert MacCoun & Peter Reuter, Keynote Address at the Michigan State University
Journal of Medicine & Law Symposium: Exploring Drug Depenalization: The Next Step After Proposal
1 (Apr. 10, 2009) (distinguishing Michigan‘s medical marijuana law from California‘s law); Hoffmann
& Weber, supra note 12, at 1453–56 (discussing variations in state medical marijuana laws, including
differences in covered medical conditions and allowable quantities).
48. See infra Part III (discussing potential models to accomplish this goal).
49. See 18 Legal Medical Marijuana States and DC: Laws, Fees, and Possession Limits, PROCON,
http://medicalmarijuana.procon.org/view.resource.php?resourceID=000881 (last updated Feb. 22, 2013,
5:21 PM) (comparing medical marijuana state laws in terms of the year passed, fee, and possession
limit); Hoffmann & Weber, supra note 12, at 1454, 1456 tbl.2 (reporting that most states regulate the
amount of marijuana that patients or caretakers may possess and giving examples of variations in state
amount requirements).
50. See Hoffmann & Weber, supra note 12, at 1456 tbl.2 (demonstrating that while California,
Maine, Rhode Island, and New Jersey allow marijuana dispensaries, other states including Alaska,
Oregon, and Washington do not).
51. See id. at 1454 (reporting that most state laws do not have specific provisions regulating
dispensaries, whereas California allows dispensing of medical marijuana through cooperatives or
collectives).
52. See id. at 1454, 1455 tbl.1 (reporting that different states allow use of medical marijuana for
different diseases and conditions; for instance, Michigan and Rhode Island allow marijuana use for
Hepatitis C while California and New Jersey do not allow such use).
53. Compare CAL. HEALTH & SAFETY CODE § 11362.79 (West 2007 & Supp. 2013) (providing that
California prohibits a qualified patient from smoking medical marijuana in certain places including
where smoking is illegal, in or within 1,000 feet of school, or on a school bus), with ALASKA STAT. §
17.37.040 (2012) (noting that in Alaska, medical use of marijuana is prohibited in any place of
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including location of use, responsibilities of physicians (e.g., whether alternative
treatment was attempted),54 regulation of caregivers,55 ability of local governments
to set additional controls on cultivation and distribution, 56 establishment of
registries,57 and whether qualified users are protected from arrest and/or
prosecution.58 In broader terms, MML creates legal frameworks that vary in the
balance each jurisdiction creates between access and restrictiveness.
A. The Role of Dispensaries: A New Kind of Pharmacy?
Marijuana, including medical marijuana, is a Schedule I controlled
dangerous substance. 59 As such, its possession and/or use in the United States is
illegal. 60 As far as the federal government, through the Drug Enforcement
Administration (DEA) is concerned, it has no acceptable medical use, thus
maintaining marijuana‘s Schedule I status. 61 Residents in states with medical
marijuana decriminalization statutes cannot use the U.S. Constitution,
principally the Commerce Clause, as a shield. 62 In 2009, the Department of
Justice issued a memorandum to U.S. Attorneys that federal resources should
not be used to prosecute people whose actions are in compliance with state laws

employment, in any medical facility monitored by the department or the Department of Administration,
on or within 500 feet of school grounds, or on a school bus).
54. See MARIJUANA POLICY PROJECT, STATE-BY-STATE MEDICAL MARIJUANA LAWS: HOW TO
REMOVE
THE
TREAT
OF
ARREST
app.
H
(2011),
available
at
http://www.mpp.org/assets/pdfs/library/State-by-State-Laws-Report-2011.pdf (noting that when
physicians issue a recommendation or certification to patients authorizing use of medical marijuana,
some states require that physicians discuss the risks and benefits of medical marijuana use and to include
in the certification that the patient has an approved condition).
55. Compare CAL. HEALTH & SAFETY CODE § 11362.7(e) (West 2007 & Supp. 2013) (requiring a
primary caregiver to be at least 18 years old in California), with ALASKA STAT. § 17.37.010(d) (2012)
(requiring a primary caregiver in Alaska to be at least 21 years old).
56. Compare CAL. HEALTH & SAFETY CODE § 11362.83 (West 2007 & Supp. 2013) (allowing
cities or local counties in California to enact other laws consistent with the state medical marijuana law),
with ALASKA STAT. §§ 17.37.010–080 (2012) (providing no provisions giving local governments
authority to enact additional controls).
57. See Hoffmann & Weber, supra note 12, at 1454, 1456 tbl.2.
58. See id.
59. Controlled
Substances,
U.S.
Dep‘t
of
Justice,
3
(Sept.
6,
2012),
http://www.deadiversion.usdoj.gov/schedules/orangebook/e_cs_sched.pdf.
60. See id. See also Marsha N. Cohen, Breaking the Federal/State Impasse Over Medical
Marijuana: A Proposal, 11 Hastings Women‘s L.J. 59, 60–61 (2000) (discussing the prohibition of use
and possession of Schedule I controlled substances).
61. See OFFICE OF DIVERSION CONTROL, Controlled Substance Schedules, U.S. DEP‘T OF JUSTICE,
http://www.deadiversion.usdoj.gov/schedules/ (last visited Apr. 1, 2013) (noting that marijuana, as a
Schedule I Controlled Substance, has no accepted medical use and a high likelihood for abuse).
62. See Gonzales v. Raich, 545 U.S. 1, 22 (2005) (holding that application of the Controlled
Substance Act to intrastate growers and users of medical marijuana was within Congress‘s Commerce
Clause powers, meaning it cannot be used as a shield to prevent criminal liability for marijuana
manufacturing).
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providing for use of medical marijuana. 63 It is important to note that this
memorandum did not change the law, was not binding on the U.S. Attorneys,
and that the Administration could easily reverse its position. 64
In fact, despite the policy stated above, there appears to be a lessening of the
federal tolerance for medical marijuana at least as it relates to dispensaries. A
number of states allow these dispensaries, California having the largest number, but
dispensaries were not necessarily included in the federal government‘s tolerance of
state medical marijuana decriminalization laws. 65 In October 2011, California‘s
four U.S. Attorneys, including Sacramento‘s U.S. Attorney, held a press conference
to announce the federal government‘s intention to crack down on medical
marijuana dispensaries.66 The federal government sent out letters to dispensaries
and their landlords in San Francisco, San Diego, and Marin County that
dispensaries were in violation of federal law. 67 The letters instructed the landlords
to evict their dispensary tenants.68 They also directed the dispensaries to close up
shop within forty-five days; otherwise, both the dispensary owners and the
landlords would be arrested and prosecuted.69 The government noted that it was
focusing only on those dispensaries that were ―clearly profiteering‖ from the
medical marijuana industry.70 However, by December 2011, in Sacramento,
California, ninety-one dispensaries were shut down, leaving only eight.71 In
Montana, in March 2011, federal agents raided medical marijuana dispensaries
around the state.72 More recently, in July 2012, the Department of Justice served
Harborside Health Center‘s property owners with commercial property forfeiture

63. Memorandum from James M. Cole, Deputy Att‘y Gen., to U.S. Att‘ys (June 29, 2011),
available at http://www.justice.gov/oip/docs/dag-guidance-2011-for-medical-marijuana-use.pdf.
64. See id. (emphasizing that enforcement of the Controlled Substances Act ―remains a core
priority‖ and that the Ogden Memo is only meant to guide U.S. Attorneys in exercising their ―broad
discretion‖ in prosecuting federal criminal matters).
65. See id. (noting that state-authorized dispensaries are not shielded from federal prosecution or
enforcement actions).
66. See Peter Hecht, U.S. Attorneys: Marijuana Dispensaries in California Aren’t Legal,
SACRAMENTO BEE, Oct. 7, 2011, http://blogs.sacbee.com/crime/archives/2011/10/us-attorneysmarijuana-dispensaries-in-california-arent-legal.html (reporting that federal prosecutors would be
bringing criminal complaints and forfeiture actions against numerous California medical marijuana
dispensaries).
67. See Alexander Leach, The Federal Government is Cracking Down on Medical Marijuana,
EXAMINER, Oct. 8, 2011, http://www.examiner.com/liberal-in-sacramento/the-federal-government-iscracking-down-on-medical-marijuana.
68. See id.
69. See id.
70. See id.
71. See Alexander Leach, Medical Marijuana Dispensaries are Closing Up Shop, EXAMINER, Dec.
5, 2011, http://www.examiner.com/article/medical-marijuana-dispensaries-are-closing-up-shop.
72. See Gwen Florio, Feds Raid Medical Marijuana Operations in Missoula, Statewide,
MISSOULIAN, Mar. 14, 2011, http://missoulian.com/news/local/feds-raid-medical-marijuana-operationsin-missoula-statewide/article_eae07e58-4e7d-11e0-aa23-001cc4c03286.html.
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proceedings because it violates federal law. 73 Harborside Health Center serves over
100,000 cannabis patients in two northern California cities. 74
B. FDA Approval and Risk Evaluation and Mitigation Strategies (REMS)
The use of marijuana for medical purposes is prohibited at the federal level
because of the status of marijuana as a Schedule I drug under the Controlled
Substances Act.75 Thus, unlike other drugs in the United States, medical marijuana
has not undergone approval as a new drug by the Food and Drug Administration
(FDA) and has not been subject to the same level of rigorous clinical trials that is
true for approved drugs. 76 Nor has marijuana been subject to the establishment of
safety standards that FDA may establish for drugs with a profile of side effects or
potentially harmful public health effects. 77
The FDA, for example, has developed Risk Evaluation and Mitigation
Strategies (REMS) for prescription opioid analgesics due to growing concerns
about their abuse and diversion. Over the past decade, the medical use of opioid
analgesics (OAs) have markedly increased, with OA prescriptions rising at twice
the rate of non-OA prescriptions.78 Parallel increases in OA abuse and diversion
have accompanied the rise in medical OA use. 79 In 2010, 12.2 million United States
citizens aged twelve and older reported past-year non-medical use of prescription
OAs, a ten percent increase from 2002, making OAs the most abused drugs after
marijuana.80 Consequences of OA abuse include death from poisoning and

73. See Malia Wollan, Oakland Files Suit Against U.S. to Prevent Closing of Marijuana
Dispensary, N.Y. TIMES, Oct. 12, 2012, at A18 (reporting that U.S. Attorney Melinda Haag issued a
forfeiture notice on two of Harborside‘s properties).
74. See Carly Schwartz, Harborside Health Center Community Suffers Under Federal Cannabis
Crackdown, HUFFINGTON POST (Sept. 4, 2012, 4:02 PM), http://www.huffingtonpost.com/2012/09/04/
harborside-health-center-_n_1853344.html.
75. See supra notes 59–61 and accompanying text.
76. See JOY ET AL., supra note 1, at 196 fig.5.1, 202 (displaying the various stages of testing that
drugs must undergo before receiving approval for marketing in the United States).
77. See 21 C.F.R. § 201.57(c)(6) (2012) (authorizing FDA to revise a drug‘s labeling when there is
―reasonable evidence of a causal association‖ between the drug and a potentially harmful health effect).
78. See Bridget M. Kuehn, Opioid Prescriptions Soar: Increase in Legitimate Use as Well as
Abuse, 297 JAMA 249, 249 (2007) (noting that opioid analgesics are now ―among the most prescribed
drugs‖ in the United States and providing evidence of the rise of OA prescriptions).
79. See id. at 249–50 (noting a simultaneous rise in legitimate medical OA use and illicit OA
abuse); see also SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., U.S. DEP‘T OF HEALTH &
HUMAN SERVS., RESULTS FROM THE 2007 NATIONAL SURVEY ON DRUG USE AND HEALTH 250 tbl.G.1
(2008).(illustrating the rise in illicit use of prescription pain relievers from 2002 to 2007).
80. Compare SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., U.S. DEP‘T OF HEALTH &
HUMAN SERVS., RESULTS FROM THE 2002 NATIONAL SURVEY ON DRUG USE AND HEALTH: DETAILED
TABLES tbl.1.1A (2005) (finding that 10,992,000 persons aged twelve or older reported past-year nonmedical use pain relievers in 2002), with SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., U.S.
DEP‘T OF HEALTH & HUMAN SERVS., RESULTS FROM THE 2010 NATIONAL SURVEY ON DRUG USE AND
HEALTH: DETAILED TABLES tbl.1.54A (2012) (finding that 12,213,000 persons aged twelve or older
reported past-year non-medical use pain relievers in 2010).
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overdose,81 increases in an already overburdened treatment system, with non-heroin
OA abuse treatment admissions increasing from 22,600 admissions in 1999 to over
142,000 in 2009.82 The economic burden of OA abuse and dependence remains
substantial, with total societal costs estimated at $55 billion. 83 It would be difficult
if not impossible to develop REMS for medical marijuana due in part to the
inability to clearly identify the plant a particular individual might be using. 84 There
is obviously no standardization since it is not even acknowledged by the federal
government as having an accepted medical use.85 That is not to say that a medical
body might be able to develop some guidelines for its safe use and publish those in
some standard form.
Although FDA-approved products that contain cannabis (e.g., Marinol®)
exist, there has been a sustained push for states to decriminalize medical
marijuana.86 FDA approval of medical marijuana as it currently exists, even if
allowed under the federal Food Drug and Cosmetic Act, is impractical—marijuana
used for medical purposes is not a single plant variety or strain.87 Indeed, it is the
variability in plant differences in potency and effects, as well as the flexibility in
dosage and administration, that lead many patients to prefer plant-sourced cannabis

81. See Leonard Paulozzi et al., CDC Grand Rounds: Prescription Drug Overdoses – a U.S.
Epidemic, 61 Morbidity & Mortality Wkly. Rep. (Ctrs. for Disease Control & Prevention, Atlanta, Ga.),
Jan. 13, 2012, at 10, 10 (commenting that OAs are responsible for an increasing number of unintentional
overdose deaths); Margaret Warner et al., Increase in Fatal Poisonings Involving Opioid Analgesics in
the United States, 1999–2006, 22 NCHS DATA BRIEF (Nat‘l Ctr. for Health Statistics, Hyattsville, Md.),
Sept. 2009, at 1, 1 (finding OA-related deaths are responsible for an increasing percentage of drug
poisoning deaths); Leonard Paulozzi et al., Increasing Deaths from Opioid Analgesics in the United
States, 15 Pharmacoepidemiology & Drug Safety 618, 621–22 (2006) (noting that OA poisoning is the
most rapidly increasing category of poisoning death of any major drug).
82. Compare CTR. FOR BEHAVIORAL HEALTH STATISTICS & QUALITY, SUBSTANCE ABUSE &
MENTAL HEALTH SERVS. ADMIN, 1999 Substance Abuse Treatment Admissions by Primary Substance
of Abuse According to Sex, Age Group, Race, and Ethnicity, TREATMENT EPISODE DATA SET,
http://wwwdasis.samhsa.gov/webt/quicklink/US99.htm (last visited Mar. 30, 2013) (citing 22,637 nonheroin OA abuse treatment admissions in 1999), with CTR. FOR BEHAVIORAL HEALTH STATISTICS &
QUALITY, SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., 2009 Substance Abuse Treatment
Admissions by Primary Substance of Abuse According to Sex, Age Group, Race, and Ethnicity,
TREATMENT EPISODE DATA SET, http://wwwdasis.samhsa.gov/webt/quicklink/US09.htm (last visited
Apr. 1, 2013) (citing 143,564 non-heroin OA abuse treatment admissions in 2009).
83. Howard Birnbaum et al., Societal Costs of Prescription Opioid Abuse, Dependence, and Misuse
in the United States, 12 Pain Med. 657, 661 (2011) (estimating the total societal costs of OA abuse to be
55.7 billion dollars in 2007 and providing a breakdown of those costs).
84. See Shannon L. Datwyler & George D. Weiblen, Genetic Variation in Hemp and Marijuana
(Cannabis sativa L.) According to Amplified Fragment Length Polymorphisms, 51 J. FORENSIC SCI. 371,
371 (2006) (noting the substantial variation in drug content among cannabis plants).
85. See supra notes 59–61 and accompanying text.
86. See PROCON, supra note 3.
87. See JOY ET AL., supra note 1, at 215–16 (outlining the regulatory hurdles medical marijuana
cultivators would face in seeking FDA approval even if it were allowed under the Food Drug and
Cosmetic Act, such as difficulties meeting the safety and efficacy standards as both a botanical product
and as a drug delivered through smoke inhalation).
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over Marinol® and other synthetic prescription products. 88 Cannabis plants have
psychoactive properties, produced from the over eighty phenols and flavonoids in
the plants; many of these compounds are thought to have medicinal properties. 89 In
particular, cannabis plants produce a unique family of terpenophenolic compounds
called cannabinoids.90 Two cannabinoids of particular medical utility include Delta9-tetrahydroccannabinol (THC), which has psychoactive properties, and
Cannabidiol (CBD), which does not.91 Marinol® only includes THC, and does not
include cannabidiol or other phenolic or flavonoid compounds.92
Medical marijuana would be a prime candidate for a REM if approved by
FDA as a new drug because there would likely be an authorized source such as the
University of Mississippi where the plant variety/species would be standardized
and appropriate information about its use and potential risks could be developed
with some level of confidence.93 Even without FDA-approval, however, states
could adapt REMS-like requirements as part of their MML. 94 To date, no state has
implemented such safeguards.95
C. Prescription Drug Monitoring Programs
In response to the growing epidemic of prescription drug abuse, states have
implemented prescription drug monitoring programs (PDMPs), state-level
registries that monitor the prescribing, dispensing, and purchase of prescribed

88. See generally Ernest Small & H.D. Beckstead, Common Cannabinoid Phenotypes in 350 Stocks
of Cannabis, 36 Lloydia 144 (1973) (analyzing variances in content among 350 unique strains of
cannabis); Cohen, supra note 60, at 71–72 (noting that Marinol® fails to satisfy patient due to its
inflexible dosage and administration, adverse side-effects, and high cost).
89. Geraint B. Osborne & Curtis Fogel, Understanding the Motivations for Recreational Marijuana
Use Among Adult Canadians, 43 SUBSTANCE USE & MISUSE 539, 551 (2008).
90. Id.
91. See Teresa Iuvone et al., Neuroprotective Effect of Cannabidiol, a Non-psychoactive
Component from Cannabis sativa, on ß-amyloid-induced Toxicity in PC12 cells, 89 J. NEUROCHEMISTRY
134, 135 (2004).
92. PAUL ARMENTANO, NORML, MARINOL VERSUS NATURAL CANNABIS: PROS, CONS AND
OPTIONS
FOR
PATIENTS
5
(2005),
available
at
http://norml.org/pdf_files/NORML_Marinol_vs_Natural_Cannabis.pdf.
93. See FDA Partnership, U. MISS. SCH. PHARMACY, NAT‘L CENTER FOR NAT. PRODUCTS RES.,
http://www.pharmacy.olemiss.edu/ncnpr/fdapartnership.html (last visited Apr. 1, 2013) (stating that
FDA and the University of Mississippi School of Pharmacy have partnered to develop a research
program to specifically study botanical supplements).
94. See FOOD & DRUG ADMIN., DRAFT GUIDANCE: FORMAT AND CONTENT OF PROPOSED RISK
EVALUATION AND MITIGATION STRATEGIES (REMS), REMS ASSESSMENTS, AND PROPOSED REMS
MODIFICATIONS 2 (2009), available at http://www.fda.gov/downloads/Drugs/Guidances/
UCM184128.pdf (stating that FDA only requires a REMS when it needs to ensure the benefits of a
drug outweigh its risks).
95. See AM. SOC‘Y OF ADDICTION MED., PUBLIC POLICY STATEMENT ON MEDICAL MARIJUANA
(2010), available at http://www.asam.org/docs/publicy-policy-statements/1medical-marijuana-410.pdf?sfvrsn=0 (explaining that even in states that have legalized marijuana, the marijuana is not
standardized or subject it to quality controls).
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medications categorized as controlled substances. 96 A PDMP is defined as a
―statewide electronic database which collects designated data on substances
dispensed in the state.‖97 This implementation process took many years, as most
states have been historically resistant to passing laws where the state itself would
have access to a patient‘s medical record.98 Indeed, this issue of privacy has been a
strong objection on the part of those who oppose state laws. 99
As of 2012, forty-eight states had enacted or authorized a PDMP;100 and of
these, at the time of publication, forty-three are operational.101 Despite widespread
adoption, few studies have evaluated PDMP effectiveness in reducing prescription
abuse or assessed their impact on patient care and outcomes.102 State variability in
PDMP design, scope, operationalization, and rigor imposes unique challenges in
assessing PDMP effectiveness.103 Although all PDMPs use electronic technology to
collect, transmit, and organize prescription data,104 three states (New York,
California, and Texas) supplement their electronic system with ‗hard copy‘
serialized and/or tamper-proof paper forms, a deterrent to prescription alterations
and forgeries.105 Critics of PDMPs contend these forms reduce patient access to

96. See OFFICE OF DIVERSION CONTROL, State Prescription Drug Monitoring Programs, U.S.
DEP‘T OF JUSTICE, http://www.deadiversion.usdoj.gov/faq/rx_monitor.htm (last updated Oct. 2011).
97. Id.
98. See KAREN BLUMENSCHEIN ET AL., UNIV. OF KY., REVIEW OF PRESCRIPTION DRUG
MONITORING PROGRAMS IN THE UNITED STATES 3–4 (2010) (recommending that PDMP programs not
allow data to be open to the public or subject to open record laws amidst privacy concerns).
99. See, e.g., California Medical Privacy Fact Sheet C4: Your Prescriptions and Your Privacy,
PRIVACY RIGHTS CLEARINGHOUSE (July 2012), https://www.privacyrights.org/fs/fsC4/CA-medicalprescription-privacy#prescription-drug-monitoring-program (stating that PDMPs create privacy
concerns by putting users‘ information into a database accessible to other people and governmental
entities).
100. See Status of State Prescription Drug Monitoring Programs, NAT‘L ALLIANCE FOR MODEL ST.
DRUG LAWS, 2 (July 2, 2012), http://www.namsdl.org/documents/PMPProgramStatus07022012.pdf.
101. Id.
102. See Jeanmarie Perrone & Lewis S. Nelson, Medication Reconciliation for Controlled
Substances–An ―Ideal‖ Prescription-Drug Monitoring Program, 366 NEW ENG. J. MED. 2341, 2341
(2012) (noting the limited amount of research on PDMP effectiveness is a result of differing PDMP
designs across states).
103. Id.
104. See id. (discussing how PDMPs have benefited from technological advancements).
105. See N.Y. STATE DEP‘T OF HEALTH, WHAT EVERY PRACTITIONER NEEDS TO KNOW ABOUT
CONTROLLED SUBSTANCE PRESCRIBING 2 (2009), available at http://www.health.ny.gov/
publications/1477.pdf (describing the requirement of New York practitioners to keep written records of
all prescribed controlled substances); Scott M. Fishman, Repeal of Triplicate Prescribing and the New
Security Paper Prescription Requirement in California, CSA BULLETIN (Cal. Soc‘y of
Anesthesiologists, San Mateo, Cal.), Jan.–Mar., 2004, at 2 (stating that California requires the use of
tamper-resistant security paper for all controlled drugs prescribed); Texas Prescription Program, TEX.
DEP‘T
PUB.
SAFETY,
http://www.txdps.state.tx.us/RegulatoryServices/prescription_program/
prescriptionforms.htm (last visited Apr. 1, 2013) (stating that Texas practitioners use single or multiple
copy forms issued by the state to write prescriptions for certain controlled substances).
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necessary medications due to the ―chilling effect‖ on prescribers who fear scrutiny
of their practices.106
Since the most comprehensive empiric work evaluating PDMPs was
conducted a decade ago on the New York paper-based benzodiazepine PDMP
program,107 only a few single-state108 and multiple-state109 analyses have been
conducted. This research finds PDMPs are associated with reductions in
prescribing of targeted medications. Although one study found PDMP states
experienced both lower OA supply and treatment admissions than non-PDMP
states,110 another study found PDMPs that communicated with prescribers and
pharmacists achieved a ten percent reduction in the use and abuse of monitored
prescription drugs.111 To date, only one has documented opioid analgesic

106. See, e.g., Jing Wang & Paul J. Christo, The Influence of Prescription Monitoring Programs on
Chronic Pain Management, 12 PAIN PHYSICIAN 507, 510 (2009) (noting that physicians may under-treat
pain in order to avoid investigations by regulatory agencies).
107. In 1989, New York State implemented regulations requiring all benzodiazepines prescriptions
to be written on special triplicate prescription forms, a measure that had significant effects on
benzodiazepine use. See, e.g., Benzodiazepines: Additional Effects of The Triplicate Program, 90 N.Y.
ST. J. MED. 273, 273 (1990); Benzodiazepines: Prescribing Declines Under Triplicate Program, 90
N.Y. ST. J. MED. 218, 218 (1990); Michael Weintraub et al., Consequences of The 1989 New York State
Triplicate Benzodiazepine Prescription Regulations, 266 JAMA 2392, 2392 (1991); Sallie-Anne
Pearson et al., Racial Disparities In Access Following Regulatory Surveillance of Benzodiazepines, 166
ARCHIVES INTERNAL MED. 572, 575 (2006); Anita K.Wagner et al., Effects of State Surveillance on New
Post-Hospitalization Benzodiazepine Use, 15 INT‘L J. QUALITY HEALTH CARE 423, 426 fig.1, 427
(2003).
108. See, e.g., Aaron M. Gilson et al., Time Series Analysis of California’s Prescription Monitoring
Program: Impact On Prescribing And Multiple Provider Episodes, 13 J. PAIN 103, 104 (2012)
(analyzing California‘s use of tamper-resistant prescription forms to determine whether forms affected
doctors‘ prescribing practices for Schedule II opioids); Katherine A. Sigler et al., Effects of Triplicate
Prescription Law On Prescribing of Schedule II Drugs, 41 AM. J. HOSP. PHARMACY 108, 108 (1984)
(studying Texas‘ triplicate prescription program‘s prescribing patterns for Schedule II substances);
Nathaniel Katz et al., Usefulness of Prescription Monitoring Programs For Surveillance — Analysis of
Schedule II Opioid Prescription Data In Massachusetts, 1996–2006, 19 PHARMACOEPIDEMIOLOGY &
DRUG SAFETY 115, 116 (2010) (analyzing Massachusetts‘ prescription monitoring program and opioid
prescribing and usage trends).
109. See e.g., Leonard J. Paulozzi et al., Prescription Drug Monitoring Programs And Death Rates
From Drug Overdose, 12 PAIN MED. 747, 749 (2011) (comparing drug overdose mortality rates in states
with PDMPS with states without PDMPs); U.S. GEN. ACCOUNTING OFFICE, GAO-02-634,
PRESCRIPTION DRUGS: STATE MONITORING PROGRAMS PROVIDE USEFUL TOOL TO REDUCE DIVERSION
15 (2002) (reporting the success of PDMP programs in certain states, including Kentucky, Nevada, and
Utah); Richard M. Reisman et al., Prescription Opioid Usage And Abuse Relationships: An Evaluation
of State Prescription Drug Monitoring Program Efficacy, 3 SUBSTANCE ABUSE: RES. & TREATMENT 41,
43 (2009) (studying PDMP programs in several states between 1997 and 2003); Ronald Simeone &
Lynn Holland, An Evaluation of Prescription Drug Monitoring Programs, SIMEONE ASSOCIATES, INC. 2
(Sept. 1, 2006), http://www.simeoneassociates.com/simeone3.pdf (studying the impact of PDMPs in
curbing drug supply and abuse in the United States between 1997 and 2003).
110. Reisman et al., supra note 109, at 46–47.
111. Simeone & Holland, supra note 109, at 40.
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prescribing changes associated with electronic-only PDMPs,112 although another
study found changing from a ―triplicate‖ paper-based program to one requiring an
electronic security form resulted in statistically significant increases in Schedule II
opioid analgesics, especially short-acting oxycodone and hydrocodone.113 Other
research has documented that PDMPs with paper prescription overlays experienced
both lower prescription OA use and overdose mortality rates than electronic-only
PDMPs.114 Compared to non-PDMP states, those with prescription monitoring
programs utilized greater amounts of Schedule III hydrocodone and nonsignificantly lower amounts of Schedule II opioid analgesics. 115 It is important to
note that reductions in use of prescription medications targeted by PDMPs does not
translate into a corresponding reduction in their abuse or diversion. 116 To date, no
research on PDMPs has adequately differentiated the effectiveness of PDMPs in
reducing abuse and diversion versus reducing medical access to controlled
prescription medications.117
As noted previously, the widespread acceptance of PDMPs has not resulted in
a widespread understanding of their intended and unintended impacts. PDMPs
remain contentious, with their supporters118 and detractors.119 The specter of a
chilling effect on prescribing (and dispensing) for those patients in genuine medical
need has been a prime motivator for objections. 120 Despite these concerns, the DEA

112. Linda Simoni-Wastila & Jingjing Qian, Influence of Prescription Monitoring Programs On
Analgesic Utilization By An Insured Retiree Population, 21 PHARMACOEPIDEMIOLOGY & DRUG SAFETY
1261, 1262 (2012).
113. Gilson et al., supra note 108, at 106.
114. Simoni-Wastila & Qian, supra note 112, at 1262 (finding that paper and/or form-based
monitoring systems produced a reduction in the use of opioid analgesics); Paulozzi et al., supra note
109, at 752 (noting that PDMPs resulted in lower opioid overdose mortality rates in California, New
York and Texas).
115. Paulozzi et al., supra note 109, at 751.
116. See id. at 750–51.
117. See Wang & Christo, supra note 106, at 510 (discussing conflicting results regarding the effects
of PDMPs on doctors‘ prescribing behaviors and opioid drug abuse rates).
118. See Amy Pavuk, States Could Makes Better Use of Prescription Data To Fight Drug Abuse,
Study Finds, ORLANDO SENTINEL Sept. 20, 2012, http://articles.orlandosentinel.com/2012-0920/news/os-pdmp-study-florida-20120920_1_prescription-drug-prescriptions-from-multiple-doctorsflorida-s-pdmp (discussing how supporters of Florida‘s PDMP believe it contributes to reduced drug
abuse rates).
119. See THOMAS CLARK ET AL., BRANDEIS UNIV., PRESCRIPTION DRUG MONITORING PROGRAMS:
AN
ASSESSMENT
OF
THE
EVIDENCE
FOR
BEST
PRACTICES
4
(2012),
http://www.pewhealth.org/uploadedFiles/PHG/Content_Level_Pages/Reports/PDMP%20Update%20131-2013.pdf (noting public and private supporters, including the Drug Enforcement Agency, Department
of Justice, and Purdue Pharma, the manufacturer of OxyContin); Felisa Cardone, Lawmakers May
Cancel State Database Used To Fight Prescription-Drug Abuse, DENVER POST, Mar. 7, 2011,
http://www.denverpost.com/news/ci_17553082 (discussing Colorado lawmakers‘ distrust of the state
PDMP amidst privacy concerns and a lack of information to the public).
120. See KRISTIN M. FINKLEA ET AL., CONG. RESEARCH SERV., R42593, PRESCRIPTION DRUG
MONITORING PROGRAMS 20 (2012) (discussing various organizations‘ concerns that PDMPs may limit
doctors‘ ability to adequately treat patient pain).
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and other advocates for PDMPs have been successful in convincing states to adopt
PDMPs.121 Probably the most significant tool in the DEA‘s recruiting repertoire is
the grant money from the federal government to states for program implementation
once PDMP legislation is passed.122
PDMPs are not without their benefits. They may be used to authenticate
prescribers, pharmacies, and patients. 123 They may be helpful in emergency
departments and other urgent care settings to assist in the treatment of patients who
present without known medical history. 124 The success of PDMPs may depend, in
part, on which area of the state is responsible for tracking prescriptions. 125 Is it law
enforcement, such as the Attorney General‘s office, or is it a health care entity,
such as the state public health department? Similarities abound with medical
marijuana. For instance, the Vermont Medical Marijuana Registry is housed in the
state‘s criminal information center.126 Thus, as with the problem of prescription
opioid analgesics, such decisions are important for determining the effectiveness of
medical marijuana laws in providing access when needed, and preventing diversion
as possible.127

121. See U.S. GEN. ACCOUNTING OFFICE, supra note 109, at 20 (noting how the DEA has been
supportive of states that start PDMP programs).
122. Id. See, e.g., BUREAU OF JUSTICE ASSISTANCE, U.S. DEP‘T OF JUSTICE, OMB NO. 1121-0329,
HAROLD ROGERS PRESCRIPTION DRUG MONITORING PROGRAM FY 2012 COMPETITIVE GRANT
ANNOUNCEMENT 3–4 (2012), available at https://www.bja.gov/Funding/12PDMPsol.pdf (describing a
federal grant to assist states in starting PDMPs).
123. See IJIS INST., PMP COMMITTEE PHASE II PMIX PILOT PROJECT SURVEY OF STATE
PRESCRIPTION
MONITORING
PROGRAMS
19–20
(2007),
available
at
http://www.nascsa.org/News/IIJISpmixPMPSurveyResults1.07.pdf.
124. See David F. Baehren et al., A Statewide Prescription Monitoring Program Affects Emergency
Department Prescribing Behaviors, 56 ANNALS EMERGENCY MED., 19, 22 (2010) (reporting that
PDMPs are helpful in measuring patients‘ patterns of seeking out opiate medications).
125. See generally State/Territory/District Contacts, ALLIANCE STS. WITH PRESCRIPTION
MONITORING PROGRAMS, http://www.pmpalliance.org/content/stateterritorydistrict-contacts (last visited
Apr. 1, 2013) (outlining various state agencies charged with monitoring PDMPs).
126. Medical
Marijuana
Registry,
VT.
CRIM.
INFO.
CENTER.
http://vcic.vermont.gov/marijuana_registry (last visited Apr. 8, 2013).
127. See Birnbaum et al., supra note 83, at 664 (providing that efforts to reduce prescription opioid
abuse will require involvement from a variety of parties and agencies).
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IV. CONCLUSION
In 2012, an election year, states continued to place proposed legislation for
the medical use of marijuana on their ballots.128 Given the inevitable expansion of
MML,129 it behooves policy-makers, prescribers, dispensers, and patients to
understand the legacy of allowing increased use of marijuana for medical purposes.
Such understanding requires careful evaluation of intended—and unintended—
consequences. In order to conduct meaningful evaluation, usable data should be
collected at the national level. Such data would include marijuana utilization,
reasons for utilization, and perceptions of risk of such use. National attention also
should be given to the development of model standards of practice, based on
evaluation of state MML, which could then better inform states contemplating
MML, as well as improve the programs in states with existing MML.
Meanwhile, individual states should consider implementing their own
evaluations, considering both the medical utilization of marijuana, as well as the
effects of MML on changes in recreational use (especially among youth),
admissions to substance use treatment, impaired driving and consequences, changes
in use of alternative therapies, and criminal activity. 130 As well, states should
consider implementing safeguards for medical marijuana expansion, including the
use of patient medguides, registries, and other REMS-like components.131
Expansion of legislation for medical marijuana can provide benefits, but can also
involve risks. In order to best understand the tenuous balance of benefits and risks
in MML, understanding and evaluating current programs should be made a top
priority.

128. See Stephanie Condon, Marijuana, Same-Sex Marriage Initiatives Are Winners, CBS NEWS,
Nov. 7, 2012, http://www.cbsnews.com/8301-250_162-57546156/marijuana-same-sex-marriageinitiatives-are-winners (discussing the outcomes of proposed marijuana legislation in Colorado,
Washington, and Oregon); Chelsea Conaboy & Zachary T. Sampson, Mass. Voters OK Marijuana For
Some
Medical
Conditions,
BOSTON
GLOBE,
Nov.
7,
2012,
http://www.bostonglobe.com/metro/2012/11/07/medical-marijuana-ballot-question/OmjNOajRHvy
DgcUMVusz8H/story.html (discussing the successful outcome of Massachusetts‘ medical marijuana
legislation).
129. See The Expansion Of Medical Marijuana Acceptance Across The USA Progresses With
Massachusetts, Montana (And Arkansas Too Close To Call) Joining 13 Other States, PR NEWSWIRE,
Nov.
7,
2012,
http://www.prnewswire.com/news-releases/the-expansion-of-medical-marijuanaacceptance-across-the-usa-progresses-with-massachusetts-montana-and-arkansas-too-close-to-calljoining-13-other-states-177642701.html (discussing the increase in medical marijuana acceptance in the
United States).
130. See supra Part II.A.
131. See supra Part III.

